Avicanna Posts Record Q1 2026 Revenue on Canadian Growth, but EBITDA Slips
Event summary
- Avicanna reported record Q1 2026 revenue of $6.68M, up 6% YoY, driven by 24% growth in Canadian product sales.
- Gross profit rose 7% YoY to $3.84M, but adjusted EBITDA swung to a loss of $0.15M from a $0.43M profit.
- MyMedi.ca unit sales hit 220,246, with Avicanna-branded products up 42% YoY.
- SMGH completed its first commercial export of organic-certified flower to Australia.
- Board refreshed with three new directors, including global pharma and capital markets executives.
The big picture
Avicanna’s Q1 2026 results highlight the tension between commercial expansion and profitability, as product sales growth offset higher-margin licensing revenue. The board refresh suggests a strategic pivot toward global pharma expertise, aligning with the company’s push into clinical development. The U.S. rescheduling of cannabis could unlock new opportunities, but execution risks remain as Avicanna balances commercial and pharmaceutical ambitions.
What we're watching
- Commercial Execution
- Whether Avicanna can sustain product-driven growth while maintaining gross margins amid revenue mix shifts.
- Pharma Pipeline
- The pace at which clinical trials progress and whether they validate Avicanna’s proprietary formulations.
- Regulatory Tailwinds
- How U.S. rescheduling of cannabis impacts Avicanna’s market entry strategy and R&D investments.